The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Chief ramper Drb83 seems to have scuttled off
Could be worse, I almost put my remaining pennies in here for the update after the disaster that was ADV. If i'd done you'd probably have to scrape me off the pavement.
Dog walk it's the only way to go, next stop r and d update.
Brilliant- revenues 2m short of expectations but money coming in and not being squandered as some were suggesting. Cash is king and we have over £100m in the bank - a substantial uplift.
All the rumours around Ajan and MRHA investigations were unfounded - no skeletons in the closet.
Likely to see traders and shorters move on now as the uncertainty diminishes and excitement dies down. So, expect some volatility as they exit.
Then wait for the updated broker forecasts. I'm expecting these to be very bullish. We are currently priced at PE of around 3.5, which is simply ludicrous.
With the uncertainty now gone, this should at last start to bring in ii to replace traders and we can look forward to calmer waters and the long slow march back up.
New outbreaks, dispute resolution or M&A in line with growth strategy could, of course, still see further step changes in SP at any time.
The strategy is sound. Focus on tests that the market wants. Don't waste money developing brilliant tests that can't be sold. Don't focus on unreliable UK Gov. Expand direct sales into adjacent markets and use cheapet distributor networks elsewhere.
Stay in bed with NGOs. The pandemic will linger and have greatest impact on the unvacciinated, largely in the third wold. Developing countries and WHO will now start to invest in surveillance programs to detect and contain future viruses. We look to be positioning ourselves for some lucrative contract bids here.
We remain top end on quality, with a focus on research and scientific community - so the gold standard reputation and products used as a benchmark for all others will remain.
So will I.
@B2HS2L
Re TATA. could this be under negotiation, DA can’t say anything. Dancing around handbags! TATA would have us for breakfast! So many links to TATA MD …. Sachet Chopra liking the NCYT Group stand at the current ME show. TATA using MyGo yet no reference to this in RNS.
HKK - not quite true.
Guidance mentioned down £3m, but we also had extra £4m DHSC contract in summer, outside of private sales.
£95m revenue puts us as £6m (6%) lower than guidance.
Disappointing, but market's full of ****e at the moment, so an extra £1m in profits wouldn't have improved the SP.
Will we get more RNS,s today?,ie director buys,share buy back etc.
Before reading the RNS I searched for TATA. :o(
I like they are consolidating brands - good move
Cash & debt position is awesome
Hoped they’d beat guidance by 10% but were only slightly under so a minor disappointment
The 50% reduction on covid testing is causing the negative market reaction
DHSC is moot as factored in accounting wise ages ago
Let’s hope they spend that cash wisely on acquisitions or new products
For a company with strong cash & no debt the market cap seems unfair but I guess the outlook is where folks are unsure
This is classic example of impatient giving to the patient. Buy high sell low, classic pi.
Initially thoughts 101 mil cash fantastic
Respiratory Q4 mehh
Should have said January sales were very positive.
55% of sales outwith UK nice.
25 mil of cash should be on an accretive purchase sooner rather than later.
Byp good luck with your new strategy just don't use the board like a see saw.
It's a crying shame that the Government has been happy to fork out over £5billion in fraudulent furlough claims without bothering to check while screwing over British testing companies - not just NCYT although I think we took the biggest hit. But assuming we do eventually get our £40m+ from DHSC, the company is currently valued at just over cash in bank. Which is absurd.
It's definitely like ground hog day here.same **** re revenue recognition, debtors, cash .
For some, It's not about minute by minute share price .. or whining about not being updated on nothing to be updated about, else it would nlbe rns'd.
Then there's some one.post pricks appearing again..
always was if you are truthful.... ???
The only thing that was decent was the cash position. Everything else was fluff and that’s all DA could come up with in 100 days? This stock has just become a trading share for me.
Oriens - if revenue recognition principles have been met it should be recognised. Cash received not relevant as it’d simply sit on the balance sheet as an debtor until invoice paid.
Byp the majority here are traders, not lth's, that was a decent rns imo, until sentiment returns, it may get rough, but, I believe sentiment will return, and will go long if need be, probably not that long either!
P100...depends when payment is due, and when it will be invoiced
During my first 100 days as Chief Executive Officer of Novacyt I have undertaken a holistic review of the business and I am pleased to deliver my preliminary findings. We remain committed to becoming a leading, global clinical diagnostics company in the fight against infectious diseases, which will be enabled by strengthening the team, our core business and enhancing our position as a "global first responder" to outbreaks of novel pathogens. We will also endeavour to streamline our R&D programme to ensure we are keenly focused on commercially attractive opportunities and bringing the right solutions, to the right customers at the right time. We will also re-evaluate how we leverage our products in each of our target global markets as we continue on our path of international expansion.
Are you pleased with it losing 20% in less than 24 hours Kaeren?
I'm pleased , very pleased. I knew Omicron sales would be reflected in H1 2022 as it didnt kick off until Dec in the UK. A thorough review was what was required.
£101 million cash in the bank. No debt!!! Brilliant set of results!!! Most undervalued share on AIM imho.
Oriens - if goods sold and delivered they should be accounted for in 2021 otherwise the auditors may raise an eyebrow or two
Solid rns and a future strategy, results in line with expectations and of course not including much of what will have been generated from Omicron (that's to come!). Us Suffolk boys are happy with that. Hopefully the ii's will start to take notice now? Now many diagnostics business with £100 million in the bank. Even if today's results don't alter the sp massively the future certainly looks bright. Have a great day everyone from me and Dylan.
Whilst many of us did think revenue would be higher nobody sensible thought £150m Sp28. £110m at an absolute maximum whilst I hoped for £105m.
Immaterial in the grand scheme of things and cash still what I was hoping for (which in reality is what matters).